What the Research Actually Says About the Drugs Your Vet Prescribes

Your horse pulls up sore after a hack. The vet hands you a bottle of bute and asks how many days you want. Or it is Prascend for the new PPID diagnosis. Or a quote for joint injections in both hocks. Or a handout about a new tablet called ertugliflozin meant to bring your insulin number down.

The question underneath all of these is the same. What does this drug actually do, what does long-term use look like, and is the benefit worth what you are paying in side-effect risk?

This piece walks through the medication classes you are most likely to encounter. Where multiple research groups reach the same answer, that is called out. Where studies disagree or are too small to settle the question, that is named too. None of this replaces the conversation with your vet. It is meant to make that conversation a better one.

Is bute or Equioxx safer for long-term pain?

NSAIDs (anti-inflammatory pain relievers, the bute family) are the most-prescribed drug class in horse medicine. Three molecules dominate.

Phenylbutazone, which everyone calls bute, is the oldest and cheapest. It blocks the prostaglandins involved in inflammation, but it also blocks the ones that protect your horse's stomach lining and kidney blood flow. A short course in a healthy adult is usually fine. High doses, dehydration, foals, ponies, or many weeks of continuous dosing push the GI (gastrointestinal) side-effect rate up. The headline risk is right dorsal colitis, which is a kind of ulceration of the colon, and it depends on dose and duration.

Firocoxib (sold as Equioxx in the equine paste and Previcox in the canine tablet) is more selective. It mostly leaves the protective prostaglandins alone, so the stomach lining stays better defended. A 2024 trial comparing firocoxib against flunixin after colic surgery found firocoxib worked just as well for pain control with a friendlier side-effect profile [1]. For an older horse on long-term arthritis management, firocoxib has the cleanest safety record of the three.

Flunixin meglumine (Banamine) is the workhorse for gut pain and endotoxaemia (the systemic shock that comes with severe colic or infection). It is a non-selective blocker like bute, and its anti-endotoxic punch makes it the default for colic, post-surgical pain, and any case where the horse is genuinely sick. GI risk in long courses looks like bute's.

The owner-decidable question is which drug for which job, and how long. Studies show firocoxib for chronic musculoskeletal pain, flunixin for short-course gut and post-surgical use, and bute as a low-cost short course in healthy adults. None is "safer" in the absolute. All three become risky as the dose creeps up, courses extend past a few weeks, or your horse is dehydrated, hypovolaemic, or already losing protein into the gut.

Verdict , worth it with caveats: Match the NSAID to the job. Firocoxib (Equioxx) for long courses. Flunixin (Banamine) for gut pain and endotoxaemia. Bute for short courses in healthy adults. None of them is safe at high doses indefinitely.

Does Prascend really fix Cushing's?

Pergolide, sold as Prascend, is the only drug for PPID (pituitary pars intermedia dysfunction, the condition most owners still call Cushing's) with a meaningful long-term evidence base. It is a dopamine agonist, which is the technical way of saying it replaces a brain signal that PPID horses lose. PPID is fundamentally a loss of dopamine's normal calming effect on a part of the pituitary, so Prascend is treating the actual cause rather than masking signs.

The research here is strong. A 2020 systematic review, long-term outcome work through 2025, the 2024 BEVA primary care guideline, and replicated dose-response work all line up [2, 3, 4]. Prascend reliably brings the ACTH hormone (the marker your vet checks) back toward normal in most treated horses. It improves the underlying insulin issues in a subset. The long-term cohort data show acceptable safety on continued daily dosing.

What Prascend does well: it controls the hormone signal that drives the metabolic and immune problems of PPID. Coat shedding improves in most. Over months, not days, your treated horse looks and behaves more like an age-matched horse without PPID.

What Prascend does not do: it will not reverse advanced muscle wasting, will not fully restore lost bone density (a 2024 paper documented decreased lumbar bone density in PPID horses, only partially responsive to treatment), and does not replace the rest of senior-horse care [5]. Dose titration based on seasonal ACTH testing is now standard. Underdosing is more common than overdosing, and "Prascend isn't working" usually means the dose is too low.

Verdict , worth it: Prascend is the standard treatment for PPID and the research backs it. Effects are gradual. Dose matters. Test ACTH seasonally and adjust.

Are joint injections worth repeating?

Joint injections are the most-asked-about drug decision in performance-horse medicine. The product menu has expanded a lot, with PRP, Pro-Stride (autologous protein solution), polyacrylamide hydrogels, stem cells, hyaluronic acid, and IRAP all competing for attention. The longest-evidence option is still triamcinolone, a corticosteroid used IA (intra-articular, meaning injected directly into the joint).

Studies show triamcinolone reliably reduces lameness and joint inflammation in most joints in most horses. Decade-spanning data and recent comparisons against newer biologics in client-owned horses keep landing the same place [6, 7]. The argument against triamcinolone has never been about whether it works in the short term. It has always been about repeat use and the risk of laminitis or metabolic flare-up in horses already prone to either.

Repeat-injection safety studies through 2024 have not found catastrophic cartilage damage at clinical doses, but they have refined the dose ceilings and shown chemical signs of stress in joint fluid with frequent re-injection. A 2021 study in client-owned horses also found that intrasynovial triamcinolone treatment was not associated with incidence of acute laminitis [8]. Triamcinolone is still a defensible first choice in horses without insulin issues or laminitis history. If your horse has metabolic flags, the case for a non-steroid alternative gets stronger.

The newer products sit in a "mixed evidence" tier. Each has prospective work in its favour. None has the depth of comparison data that triamcinolone has built up. A reasonable question to ask your vet: does this horse have a reason not to use the longest-evidence option, and if so, has the alternative actually been tested for this specific lesion?

Verdict , worth it: Intra-articular triamcinolone is the longest-evidence option for symptom control in horses without metabolic flags. Newer biologics have data, but not the same depth. Skip steroids if your horse has laminitis history.

What about the new diabetes drugs (SGLT2 inhibitors)?

This is the fast-moving front, so any verdict written about it should be dated. Ertugliflozin, canagliflozin, dapagliflozin, and velagliflozin are SGLT2 inhibitors (a drug class developed for human type-2 diabetes). They cause your horse's kidneys to dump glucose into the urine, which lowers blood sugar and, in horses, can dramatically lower circulating insulin in cases that have failed dietary management.

As of mid-2026, the evidence base includes several controlled equine trials. Velagliflozin has 16-week safety and efficacy data [9, 10]. Canagliflozin has a randomised controlled trial in insulin-dysregulated horses (2023) and refractory-laminitis case work [11, 12]. Dapagliflozin and ertugliflozin have short-term clinical and biochemical response data from 2025 [13].

Studies show SGLT2 inhibitors lower insulin reliably in laminitis-prone horses whose numbers will not come down with diet and exercise alone. The same studies also identify a consistent adverse signal: hypertriglyceridaemia, which is dangerously high blood fat, sometimes severe. Multiple reports document this across the different molecules, and routine blood-fat monitoring is now standard [14, 15]. The multi-year studies that would settle whether long-term SGLT2 inhibition has bone, liver, or other consequences in horses do not yet exist.

These drugs are off-label. They are expensive. They are not first-line. They sit behind dietary management, weight loss, and foundational metabolic care. Where they earn their place is in the laminitis-history horse whose insulin will not come down with management alone.

Verdict , mixed evidence with caveats (as of May 2026): SGLT2 inhibitors lower insulin reliably in refractory cases. They cause high blood fat often enough that your vet should be checking triglycerides routinely. Long-term safety data do not yet exist. Reserve for cases that have already failed diet and exercise.

Should young horses in training get bisphosphonates?

Bisphosphonates (a drug class affecting bone metabolism, sold for horses as Tildren and Osphos) bind to bone and shut down the cells that break it down. In horses they have been used for navicular disease, suspensory injuries, and various bone-pain presentations.

The evidence is genuinely mixed and the regulatory mood has tightened. Bisphosphonates lock into bone matrix and stay there for years [16]. In a fully grown horse with a clear navicular diagnosis, the trade-off is a known disease against a drug with short-term symptom benefit and uncertain long-term remodelling effects [17]. In a young horse still building bone under training load, the same drug is being applied to a skeleton that is still actively adapting. Whether shutting down those bone-breakdown cells during that window has consequences for adaptive remodelling, fracture risk, or stress-fracture patterns is not settled by the equine research [18].

The licensed labels for these products do not include horses under four in most major jurisdictions. The peer-reviewed evidence base is thin compared to how often these drugs get used off-label, and the long-term cohort studies that would settle the young-horse question are still being collected.

Verdict , mixed evidence, lean toward caution: Bisphosphonates have short-term benefit in some bone-pain cases. Long-term effects on growing or training bone are not settled. The label restrictions exist for a reason.

Are antibiotics after surgery worth it?

Studies find that extended antibiotic use after colic surgery does not earn its place. A 2026 Equine Veterinary Journal trial looked specifically at how long to give antibiotics after colic surgery and tracked both clinical complications and the resistance signal in the gut afterward. Long courses did not reduce complications and did increase resistance signal [19]. A 2025 systematic review of post-anaesthetic complications in adult horses landed the same direction [20]. A 2025 Veterinary Surgery paper on antibiotic use for sutured castrations agreed: routine long courses do not pay off [21].

The implication for your horse is concrete. If your discharge instructions include a full week or more of broad-spectrum antibiotics for an uncomplicated procedure, that is a fair thing to ask about. Studies support targeted, properly dosed antibiotics around the time of surgery rather than days of follow-on. Resistance is not abstract: surveillance data from multiple countries show rising resistance across the bacteria your vet actually treats, including the bugs behind eye ulcers, foal pneumonia, and surgical site infections [22, 23, 24].

A separate question concerns Rhodococcus equi screening on breeding farms. Treating subclinical foals based on screening has been flagged as a driver of multidrug-resistant Rhodococcus [25]. The evidence is moving against routinely treating foals who only test positive without showing signs.

Verdict , evidence of no effect for extended use: Long antibiotic courses after colic surgery or routine castration do not improve outcomes. They do drive resistance. Ask why a long course is being prescribed.

Has deworming changed?

The dewormer story has shifted in the last decade and most owner-facing material has not caught up. Studies show that FEC-based selective treatment (FEC means faecal egg count, a manure test that tells you which horses are actually shedding worm eggs) beats the old plan of deworming everyone every quarter.

The macrocyclic lactones (ivermectin and moxidectin, the active ingredients in most paste dewormers) used to keep eggs suppressed for 8 to 16 weeks. In current populations that is down to 4 to 5 weeks in many surveys. That is the working definition of resistance creeping in. Country-level studies from Australia, the UK, Switzerland, Sweden, and the US have all reached the same conclusion in the last five years [26, 27, 28].

The 2024 BEVA primary care guidelines on parasite control, built using formal GRADE methodology, endorse selective treatment based on faecal egg counts [29]. Tapeworm diagnosis remains the weak link [30], so a serology or saliva-based tapeworm decision combined with targeted larvicidal use for encysted small strongyles in the right season is currently the most defensible plan.

Calendar-rotation dosing of every horse every quarter is contradicted by the research. FEC-based selective treatment, with targeted treatment of high shedders and tapeworm coverage where indicated, is supported.

Verdict , worth it for selective protocols: Faecal-egg-count-based selective treatment is supported. Calendar rotation of every horse is not. Resistance to ivermectin and moxidectin is real and replicated internationally.

Where there is no evidence at all

Two categories deserve naming directly.

"Natural" pain relief alternatives, framed as substitutes for NSAIDs in horses with active inflammatory pain, do not have a peer-reviewed equine evidence base anywhere close to the depth of the conventional NSAID literature. This is absence of evidence rather than evidence of no effect. Some compounds (devil's claw, boswellia) have human or in-vitro work behind them. Equine clinical trials of the size and design that would settle whether they meaningfully replace NSAID effect do not exist. An owner picking them for comfort in a mildly arthritic retired horse is making a different decision than one picking them instead of bute for an acute laminitis case. The first the research is silent on. The second the research does not support.

Ulcer adjunct supplements sit in a similar place. Omeprazole (sold as GastroGard for treatment and UlcerGard for prevention) has the evidence base. It is the standard for squamous gastric disease (the upper-stomach ulcers most performance horses get), and the comparison trials are clear. Most "ulcer supplements" sold as adjuncts or substitutes do not have controlled trials in horses showing they prevent or heal squamous gastric disease, and several glandular-disease (lower-stomach) trials have specifically failed to find effect for compounds widely marketed for the purpose. This is closer to evidence of no effect for some products and absence of evidence for others. Worth asking specifically which trial supports any product before paying for it.

Verdict , absence of evidence: No reliable research backs "natural" alternatives as substitutes for NSAIDs in active inflammatory pain. No reliable research backs most ulcer supplements as adjuncts or substitutes for omeprazole. Ask which trial supports the product.

A decision flow that holds for any prescription

Before any drug goes home with you, four questions are worth asking out loud.

What is the indication, in plain words? Not "for inflammation," but the actual diagnosis driving the prescription. If the indication is fuzzy, the duration is open-ended, or the drug is replacing a diagnostic step that has not been done, that is worth a question.

What is the duration? Most side-effect bright lines depend on dose and how long you give it. A short course of bute looks very different from a chronic one.

What are the side-effect bright lines for this drug? Right dorsal colitis for non-selective NSAIDs. High blood fat for SGLT2 inhibitors. Resistance pressure for antibiotics. Repeat-injection load for joint steroids. These should be named at the start, not after a complication.

What does monitoring look like? Seasonal ACTH for Prascend. Triglycerides for SGLT2 inhibitors. Faecal egg counts for dewormers. Post-injection follow-up for joint medications. If monitoring is not part of the plan, ask why.

When to insist on the conversation

Push for a longer chat with your vet when a drug is being recommended for an unusually long course relative to its evidence base. When your horse has a metabolic, laminitis, kidney, or liver flag that interacts with the prescribed drug. When a treatment is being suggested as a replacement for a diagnostic step rather than the result of one. When more than one new drug is being added at once. When no recheck point is specified.

A vet comfortable being asked these questions is the vet to keep.

Bottom line

The research backs matching the drug to the actual diagnosis and the duration to the actual need. The bright lines come from dose and how long, not from the drug class label. Ask which trial supports the prescription. Ask what the monitoring plan is. Ask what would change the plan.

References

1. Ziegler AL et al. (2024). Is firocoxib as effective as flunixin meglumine in providing postoperative analgesia in horses following colic surgery? The Veterinary Record. doi.org/10.1002/vetr.3926
2. Tatum RC et al. (2020). Efficacy of pergolide for the management of equine pituitary pars intermedia dysfunction: A systematic review. The Veterinary Journal. doi.org/10.1016/j.tvjl.2020.105562
3. Rendle D et al. (2024). BEVA primary care clinical guidelines: Diagnosis and management of equine pituitary pars intermedia dysfunction. Equine Veterinary Journal. doi.org/10.1111/evj.14009
4. Knowles EJ et al. (2025). Long-term response of equids with pituitary pars intermedia dysfunction to treatment with pergolide. Journal of Veterinary Internal Medicine. doi.org/10.1111/jvim.70109
5. Welsh CE et al. (2024). Lumbar vertebral bone density is decreased in horses with pituitary pars intermedia dysfunction. Equine Veterinary Journal. doi.org/10.1111/evj.14039
6. de Grauw JC et al. (2016). Intra-articular treatment with triamcinolone compared with triamcinolone with hyaluronate: A randomised open-label multicentre clinical trial in 80 lame horses. Equine Veterinary Journal. doi.org/10.1111/evj.12383
7. Magri C et al. (2025). Treatment outcomes for equine osteoarthritis with mesenchymal stromal cells and hyaluronic acid. Equine Veterinary Journal. doi.org/10.1111/evj.14531
8. Bertin FR et al. (2021). Intrasynovial triamcinolone treatment is not associated with incidence of acute laminitis. Equine Veterinary Journal. doi.org/10.1111/evj.13361
9. Meier A et al. (2018). The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies. PLoS One. doi.org/10.1371/journal.pone.0203655
10. Sundra T et al. (2019). The efficacy and safety of velagliflozin over 16 weeks as a treatment for insulin dysregulation in ponies. BMC Veterinary Research. doi.org/10.1186/s12917-019-1811-2
11. Kellon EM, Gustafson KM (2022). Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis. Open Veterinary Journal. doi.org/10.5455/OVJ.2022.v12.i4.14
12. Sundra T et al. (2023). Short-term effects of canagliflozin on glucose and insulin responses in insulin dysregulated horses: A randomized, placebo-controlled, double-blind study. Journal of Veterinary Internal Medicine. doi.org/10.1111/jvim.16906
13. Bishop R et al. (2025). Short-term clinical and biochemical responses following treatment with dapagliflozin or ertugliflozin in horses with hyperinsulinemia: A retrospective case series. Domestic Animal Endocrinology. doi.org/10.1016/j.domaniend.2024.106894
14. Kellon EM, Gustafson KM (2023). Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors. Open Veterinary Journal. doi.org/10.5455/OVJ.2023.v13.i3.14
15. Knowles EJ, Norton EM (2024). Potential adverse effects of SGLT2i in horses. The Veterinary Record. doi.org/10.1002/vetr.4726
16. McLellan J (2022). Detection and residence time of bisphosphonates in bone of horses. Journal of Veterinary Diagnostic Investigation. doi.org/10.1177/10406387211050049
17. Mitchell A et al. (2019). Bisphosphonate use in the horse: what is good and what is not? BMC Veterinary Research. doi.org/10.1186/s12917-019-1966-x
18. Vergara-Hernandez FB et al. (2022). Is the use of bisphosphonates putting horses at risk? An osteoclast perspective. Animals. doi.org/10.3390/ani12131722
19. Leus EK et al. (2026). Effect of surgical antimicrobial prophylaxis duration for colic surgery on complications and resistome. Equine Veterinary Journal. doi.org/10.1002/evj.70137
20. de Lima MC et al. (2025). A systematic review of the prevalence of post-operative complications after general anaesthesia in adult horses (2000-2023). Equine Veterinary Journal. doi.org/10.1111/evj.14416
21. Faillace V et al. (2025). Influence of antimicrobial prophylaxis in horses undergoing sutured castrations. Veterinary Surgery. doi.org/10.1111/vsu.14256
22. Bourély C et al. (2020). Antimicrobial resistance in bacteria isolated from diseased horses in France. Equine Veterinary Journal. doi.org/10.1111/evj.13133
23. Wilson A et al. (2023). Antimicrobial prescribing and antimicrobial resistance surveillance in equine practice. Equine Veterinary Journal. doi.org/10.1111/evj.13587
24. Leus EK et al. (2026). Use of a point prevalence survey to measure antimicrobial use and antimicrobial resistance in equine veterinary hospitals. Equine Veterinary Journal. doi.org/10.1111/evj.14535
25. Bordin AI et al. (2022). Rhodococcus equi foal pneumonia: Update on epidemiology, immunity, treatment and prevention. Equine Veterinary Journal. doi.org/10.1111/evj.13567
26. Nielsen MK et al. (2023). Shortened strongylid egg reappearance periods in horses following macrocyclic lactone administration: The impact on parasite dynamics. Veterinary Parasitology. doi.org/10.1016/j.vetpar.2023.109977
27. Halvarsson P et al. (2024). Gastrointestinal parasite community structure in horses after the introduction of selective anthelmintic treatment strategies. Veterinary Parasitology. doi.org/10.1016/j.vetpar.2023.110111
28. Lüthin S et al. (2023). Strongyle faecal egg counts in Swiss horses: A retrospective analysis after the introduction of a selective treatment strategy. Veterinary Parasitology. doi.org/10.1016/j.vetpar.2023.110027
29. Rendle D et al. (2024). BEVA primary care clinical guidelines: Equine parasite control. Equine Veterinary Journal. doi.org/10.1111/evj.14036
30. Anderson HC et al. (2024). Performance of three techniques for diagnosing equine tapeworm infection. Veterinary Parasitology. doi.org/10.1016/j.vetpar.2024.110152